OTCMKTS:EVTCY Evotec (EVTCY) Stock Price, News & Analysis $4.78 +0.07 (+1.49%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.74▼$4.8250-Day Range$4.07▼$5.3452-Week Range$14.22▼$26.57Volume13,079 shsAverage Volume2,407 shsMarket Capitalization$1.58 billionP/E Ratio11.66Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsStock AnalysisChartFinancialsSEC Filings Get Evotec alerts: Email Address Ad Paradigm PressMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. About Evotec Stock (OTCMKTS:EVTCY)Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Read More EVTCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVTCY Stock News HeadlinesApril 24, 2024 | finance.yahoo.comEQEvotec SE Appoints Dr Christian Wojczewski as Chief Executive OfficerApril 23, 2024 | markets.businessinsider.comEQS-News: Evotec SE appoints Dr Christian Wojczewski as Chief Executive OfficerJuly 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.March 6, 2024 | finanznachrichten.deEvotec SE: Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The ClinicJanuary 10, 2024 | finanznachrichten.deEvotec SE: Evotec and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD TherapiesJanuary 4, 2024 | markets.businessinsider.comEvotec, Owkin Anounce A.I.-Powered Collaboration In Oncology, Immunology, And InflammationNovember 12, 2023 | finance.yahoo.comEvotec SE (NASDAQ:EVO) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | markets.businessinsider.comEQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate updateJuly 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.October 5, 2023 | finance.yahoo.com65LAB Launches in Partnership with Evotec SE and Backed by Leading Global Investors to Advance Drug Discovery and New Company Creation in SingaporeSeptember 27, 2023 | finance.yahoo.comEvotec SE: Launch of Partnering Agreement to Strengthen Biotech Innovators in Shared R&D EconomySeptember 21, 2023 | finance.yahoo.comEvotec SE (EVO) Stock Historical Prices & Data - Yahoo FinanceMay 30, 2023 | finance.yahoo.comIs There Now An Opportunity In Evotec SE (ETR:EVT)?May 14, 2023 | finance.yahoo.comEvotec SE (ETR:EVT) Shares Could Be 37% Below Their Intrinsic Value EstimateMay 13, 2023 | finanznachrichten.deEvotec SE: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023May 12, 2023 | investing.comEvotec SE ADR (EVO) Earnings Dates & ReportsMay 10, 2023 | investing.comEvotec SE ADR (EVO)May 9, 2023 | finanznachrichten.deEvotec SE: Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial ManufacturingSee More Headlines Receive EVTCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:EVTCY CUSIPN/A CIK1412558 Webwww.evotec.com Phone(494) 056-0810Fax49-40-5608-1222Employees4,200Year Founded1993Profitability EPS (Most Recent Fiscal Year)$0.41 Trailing P/E Ratio11.49 Forward P/E RatioN/A P/E GrowthN/ANet Income$7.14 million Net Margins20.85% Pretax Margin23.90% Return on Equity16.02% Return on Assets7.81% Debt Debt-to-Equity Ratio0.53 Current Ratio2.57 Quick Ratio2.50 Sales & Book Value Annual Sales$572.16 million Price / Sales2.76 Cash Flow$0.05 per share Price / Cash Flow105.53 Book Value$2.52 per share Price / Book1.90Miscellaneous Outstanding Shares330,221,000Free FloatN/AMarket Cap$1.58 billion OptionableNot Optionable Beta0.98 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesWerner LanthalerChief Executive OfficerCraig L. JohnstoneChief Operating Officer & Member-Management BoardEnno SpillnerChief Financial OfficerCord E. DohrmannChief Scientific OfficerVolker BraunSVP, Head-Investor Relations & ESGKey CompetitorsKrystal BiotechNASDAQ:KRYSOrganon & Co.NYSE:OGNNuvalentNASDAQ:NUVLBridgeBio PharmaNASDAQ:BBIOApellis PharmaceuticalsNASDAQ:APLSView All Competitors EVTCY Stock Analysis - Frequently Asked Questions How have EVTCY shares performed this year? Evotec's stock was trading at $11.73 at the beginning of the year. Since then, EVTCY stock has decreased by 59.2% and is now trading at $4.78. View the best growth stocks for 2024 here. When did Evotec's stock split? Evotec shares split on the morning of Wednesday, October 20th 2021. The 3-1 split was announced on Wednesday, October 20th 2021. The newly issued shares were issued to shareholders after the closing bell on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Does Evotec have any subsidiaries? Evotec subsidiaries include these companies: Central Glass Germany. GmbH, Central Glass Germany, Rigenerand Srl, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, Aptuit, Cyprotex, and others. How do I buy shares of Evotec? Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:EVTCY) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.